Opens in a new tab

10x Genomics v Vizgen (CFI, 22 October 2023)

Date22 October 2023
CourtCFI
DivisionHamburg (DE) Local Division
Type of actionApplication Rop 333
Registry referenceApp_49415/2024 · ORD_49705/2024
Parties10x Genomics, Inc., President and Fellows of Harvard College, v. Vizgen, Inc.

Official decision (PDF) · UPC registry entry

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

Dhenne Avocats · 10 October 2026

Our analysis

Summary

By an order of 22 October 2024 (UPC_CFI_22/2023, ACT_460565/2023, ORD_49705/2024), the Hamburg Local Division (S. Klepsch, presiding judge and judge-rapporteur, S. Schilling, M. Kokke, and A. Burrichter, technically qualified judge), on Vizgen, Inc.’s application for review under Rule 333 RoP in the action brought by 10x Genomics, Inc. and the President and Fellows of Harvard College for infringement of EP 4 108 782, varied the judge-rapporteur’s order of 15 August 2024: the claimants must produce emails, an internal FAQ document and a deposition transcript from the parallel proceedings before the Delaware court. Leave to appeal was granted.

Question

Is an order for the production of documents under Rule 190 RoP open to review by the panel, and does an abuse-of-rights defence justify production of documents from the US proceedings?

Decision

A production order is a case management decision and may be reviewed under Rule 333.1 RoP. Abuse of rights may be raised before the UPC if it relates to the contractual relationship and the subject matter of the claims. The emails may support the inference that 10x Genomics acquired and expanded its position to push out competitors, with Harvard’s knowledge, and the FAQ document that the litigation was used to unsettle customers: their production is ordered. The request concerning sales below cost is rejected, predatory pricing being a matter for competition authorities and courts. As the documents already exist in the US proceedings, production is not disproportionate, and Vizgen need not first use the 35 U.S.C. § 1782 procedure. The documents are restricted to outside attorneys registered in the CMS, to the exclusion of the parties’ employees.

Key points for practice

Provisions applied

Agreement on a Unified Patent Court
Art. 1(1), Art. 59(1) and Art. 73(2)(b)
Rules of Procedure
Rules 190, 191, 220.2, 224.1(b), 262A and 333
Regulation (EU) No 1257/2012
Art. 5(3)
Case law cited
Plant-e v Arkyne, The Hague Local Division, 4 March 2024

Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.


Going further

Lexicon: Written procedure (UPC).

Source and translations

Official source
Unified Patent Court registry link recorded in the record
Original language
not recorded
Translation available
no translation recorded the firm’s French record is a summary, not a translation
Date checked
not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

No case number recorded in this record.

Parties

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

No other decision in the corpus bears the same case number, and no appeal is documented in the corpus to date.

What the record states

Nature of the act
Application Rop 333
Outcome (Dhenne Avocats summary)
La formation ordonne aux demanderesses de produire des courriels, un document de questions-réponses et une transcription de déposition utiles à la défense d'abus de droit, sous confidentialité réservée aux avocats extérieurs. La demande relative aux ventes à perte est rejetée et l'appel autorisé.
Appeal
No appeal documented in the corpus, this does not mean that no appeal was lodged.
Instance
First-instance decision, whether it has become final is not recorded.

Patents mentioned

Related decisions cited in the analyses

Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Patents and standards

PublicationRole in the disputeFamilyStandard and declarationPoolSources
EP 4 108 782
Compositions and methods for analyte detection
recorded proprietor: Harvard University
Mentioned in the analysis (role not qualified)
Also mentioned in 18 other decision(s): NanoString Technologies v 10x Genomics (CoA, 11 March 2024) · 10x Genomics v NanoString (CFI, 19 September 2023) · 10x Genomics v Bruker Spatial Biology (CFI, 11 April 2025) · 10x Genomics v Vizgen (CoA, 11 March 2025) · 10x Genomics v Vizgen (CoA, 5 March 2025) · 10x Genomics v Vizgen (CFI, 20 December 2024) · NanoString Technologies v 10x Genomics (CoA, 10 December 2024) · 10x Genomics v Vizgen (CFI, 1 November 2024)
not recordednot recordednot recordedEspacenet · European Patent Register
existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically)
mentioned in: Dhenne Avocats analysis
The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.

Follow

Weekly summary, on Fridays.